Drug
GEN-001
GEN-001 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
2
50%
Ph not_applicable
1
25%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(1)
Other(1)
Detailed Status
Completed2
Terminated1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 22 (50.0%)
N/A1 (25.0%)
Trials by Status
terminated125%
unknown125%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer
NCT05419362
terminatedphase_2
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
NCT05998447
completedphase_1
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
NCT04601402
unknownnot_applicable
Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer
NCT05079503
Clinical Trials (4)
Showing 4 of 4 trials
NCT05419362Phase 2
GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer
NCT05998447Phase 2
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
NCT04601402Phase 1
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
NCT05079503Not Applicable
Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4